Most solid-organ cancers do not reliably show up on routine blood work, and even specialized tumor-marker tests miss a substantial share of cases. Leukemia stands out as essentially the only cancer that routine blood tests like a complete blood count (CBC) can flag on their own, because the malignant cells circulate in the bloodstream where they are directly counted and examined.1City of Hope. How to read blood test results For the vast majority of other cancers, a normal blood panel offers little reassurance, and the reasons have as much to do with anatomy and tumor biology as with the limits of any single lab test.
Why Routine Blood Tests Miss Solid Tumors
A standard CBC measures red cells, white cells, and platelets. A basic metabolic panel checks organ-function markers like kidney and liver values. Neither test was designed to look for cancer. They can sometimes hint at trouble: unexplained anemia might prompt further investigation, or elevated liver enzymes might point toward a mass in the liver. But those are indirect clues, not cancer diagnoses. Breast cancer, lung cancer, colon cancer, prostate cancer, kidney cancer, and many others can be present while every number on a routine panel sits squarely in the normal range.1City of Hope. How to read blood test results
The fundamental problem is that solid tumors grow inside organs or tissues, not in the blood itself. For a tumor’s presence to register on any blood test, it needs to shed something detectable into the bloodstream: a protein, a fragment of DNA, an unusual cell. How much of that material actually reaches a blood draw in your arm depends on the tumor’s size, its blood supply, and what barriers sit between it and your circulation.
Brain Tumors and the Blood-Brain Barrier
Brain cancers are among the hardest to pick up in blood. The brain is wrapped in a selectively permeable barrier that tightly controls what moves between brain tissue and the general bloodstream. This blood-brain barrier restricts the release of circulating tumor DNA from brain tumors into the peripheral blood, making standard liquid biopsy approaches far less effective than they are for tumors elsewhere in the body.2PubMed Central. The emerging role of circulating tumor DNA in brain tumor research Researchers have found that tumor DNA can often be detected at higher concentrations in cerebrospinal fluid than in plasma for these patients, but collecting spinal fluid requires a lumbar puncture, which is far more invasive than a blood draw.2PubMed Central. The emerging role of circulating tumor DNA in brain tumor research For now, brain tumors are typically found through imaging, prompted by symptoms like headaches, seizures, or neurological changes. Blood work plays almost no role in initial detection.
Skin Cancer Relies on Your Eyes, Not Your Veins
Most skin cancers, including melanoma, are diagnosed visually rather than through any blood test. A large Cochrane review analyzing over 34,000 skin lesions found that trained visual inspection of suspicious moles and spots achieves sensitivity above 90% in certain clinical settings, with specificity around 80%.3Cochrane Database of Systematic Reviews. Visual inspection for diagnosing cutaneous melanoma in adults No blood biomarker comes close to that performance for catching melanoma early. There are blood markers used in advanced melanoma to track disease progression, such as lactate dehydrogenase, but these are not screening tools and do not rise until the cancer has already spread. A person with an early-stage melanoma could have perfectly normal blood work for years.
This is worth underscoring because melanoma is one of the most dangerous cancers when caught late, yet one of the most curable when caught early. The detection method that works best is a skin check by a dermatologist or careful self-examination, not a lab order.
The Problem With Tumor Markers
Doctors do have blood tests designed to detect proteins associated with certain cancers. CA-125 is commonly linked to ovarian cancer, CEA to colorectal cancer, CA 19-9 to pancreatic cancer, and PSA to prostate cancer. But these markers have frustrating limitations, and their sensitivity for early-stage disease is often poor.
For ovarian cancer, CA-125 is elevated in only about half of early-stage cases. Even in advanced disease, roughly 8% of patients never show an increase.4PubMed Central. Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer This means a normal CA-125 level is not strong evidence that ovarian cancer is absent, particularly in its earliest and most treatable stages.
For colorectal cancer, CEA performs even worse as a standalone screening test. One study found CEA sensitivity at roughly 47%, with other markers like CA 19-9 and CA-125 each below 15% sensitivity for colorectal cases.5Scientific Reports. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer That means more than half of colorectal cancers would produce a normal CEA reading. These markers can be useful for monitoring treatment response or watching for recurrence in patients already diagnosed, but they are unreliable for finding cancer in the first place.
When Benign Conditions Raise the Same Markers
The flip side of low sensitivity is the false-positive problem. Many tumor markers rise in conditions that have nothing to do with cancer, which is one reason doctors do not order them as routine screening for the general population.
CA-125, for example, is produced by mesothelial cells that line body cavities. In patients with benign conditions that cause fluid accumulation in the abdomen or chest, CA-125 levels exceeded three times the normal upper limit in 77% of cases studied.6PubMed. Elevated serum CA 125 levels in patients with benign ascitic or pleural effusions Liver cirrhosis, heart failure, endometriosis, and pelvic inflammatory disease can all push CA-125 into the abnormal range. A high reading can trigger anxiety and additional invasive testing in someone who turns out to have no malignancy at all.
PSA, the prostate-specific antigen, has a similar problem. Benign prostate enlargement, prostatitis (prostate inflammation), vigorous exercise, and even recent ejaculation can all raise PSA levels. This is part of why PSA screening has been controversial: it detects many slow-growing prostate cancers that would never cause harm, while also missing certain aggressive types entirely, as discussed below.
Prostate Cancers That Don’t Produce PSA
Most prostate cancers are adenocarcinomas that produce PSA, making the protein a useful, if imperfect, screening tool. But a small fraction of prostate cancers take on a neuroendocrine form, and these tumors lose the ability to produce PSA altogether. Neuroendocrine prostate cancer typically arises when cells stop depending on androgen receptor signaling, which leads to a downregulation of PSA and other markers normally associated with the prostate.7PubMed Central. Clinical and Biological Features of Neuroendocrine Prostate Cancer
These tumors are particularly dangerous because they are aggressive and difficult to catch early. A person with neuroendocrine prostate cancer can have a completely normal PSA, and their symptoms may mimic benign urinary conditions, further delaying diagnosis.8Urology Case Reports. Oncology De novo small cell neuroendocrine prostate cancer: An atypical case presentation This is a reminder that even for cancers where a blood marker exists, there are subtypes that slip through entirely.
Your Genetics Can Make a Marker Invisible
One of the lesser-known reasons a tumor marker might return a falsely normal result has to do with your blood type, specifically a blood-group system most people have never heard of. CA 19-9, the main marker used for pancreatic and biliary tract cancers, depends on an enzyme from the Lewis blood group system for its production. People who lack certain Lewis antigens simply cannot produce CA 19-9, regardless of whether cancer is present.9PubMed Central. The Interplay Between CA19-9 and the Lewis Blood Group System: Implications for the Diagnosis of Gallbladder Cancer
This affects a meaningful share of patients. Roughly 10% of people with pancreatic ductal adenocarcinoma are Lewis-negative “nonproducers” who will never show elevated CA 19-9 no matter how advanced their cancer becomes.10Clinical Cancer Research. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC Pancreatic cancer is already notoriously hard to detect early, and for this subset of patients, the single most common blood marker for it is biochemically useless. This is a genuine blind spot in clinical practice, though clinicians increasingly recognize it and look to imaging and other markers for Lewis-negative individuals.
Kidney Cancer and Low Tumor-DNA Shedding
Kidney cancer, especially clear-cell renal cell carcinoma, is another cancer that blood tests struggle to detect. Unlike some tumors that shed large amounts of DNA into the bloodstream, kidney tumors appear to release very little. In a large clinical trial analyzing circulating tumor DNA (ctDNA) in patients with renal cell carcinoma, ctDNA was detectable at baseline in only about 5-8% of patients, depending on the assay used.11Journal of Clinical Oncology. ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial The researchers noted that while a positive result was fairly specific, the sensitivity was too low to be useful as a standalone test. For the overwhelming majority of kidney cancer patients in that trial, the blood test simply missed the cancer.
This makes kidney cancer an example of a tumor type where even next-generation liquid biopsy technology has not yet cracked the problem. Most kidney cancers are found incidentally on imaging done for other reasons, or after symptoms like blood in the urine appear.
Mucinous Tumors and Peritoneal Cancers
Certain tumors grow in ways that inherently limit their contact with blood vessels. Mucinous tumors of the appendix and colon, for instance, spread primarily across the lining of the abdominal cavity rather than invading blood vessels. The malignant cells are often sequestered within mucin pools, a gel-like substance that physically separates them from the bloodstream. This peritoneal-dominant spread, combined with low tumor cellularity and limited vascular access, means these cancers shed very little circulating tumor DNA into peripheral blood.12PubMed Central. Liquid Biopsy and Molecular Biomarkers in Mucinous Appendiceal and Colorectal Tumors: Current Evidence and Unmet Challenges in Precision Oncology
The result is that liquid biopsy tests, which rely on detecting tumor-derived material in blood, perform poorly for these cancer types. The tumors can grow extensively across the peritoneum while the blood appears clean. This is a meaningful gap because mucinous peritoneal cancers can be treated effectively if found early enough for surgical debulking, but the window for optimal treatment is often missed.
Why Tumor DNA Vanishes Quickly
Even when tumors do shed DNA into the bloodstream, the fragments do not stick around for long. Cell-free DNA in the blood has a half-life estimated at anywhere from about 16 minutes to roughly two and a half hours.13PubMed Central. Clinical Circulating Tumor DNA Testing for Precision Oncology Some estimates for specific scenarios place it as low as four minutes.14PubMed Central. Life and death of circulating cell-free DNA This rapid clearance means the body constantly sweeps away the molecular evidence of a tumor. For small or slow-growing cancers that shed only a trickle of DNA, the amount circulating at any given moment may be vanishingly small, below the detection threshold of even sensitive assays.
This creates a kind of biological timing problem. The smaller and more treatable a tumor is, the less DNA it puts into circulation, and the harder it is to detect. By the time a tumor sheds enough material to reliably appear on a blood test, it is often already at an advanced stage.
How Blood Supply and Tumor Architecture Affect Detection
You might assume that a well-vascularized tumor, one with an extensive network of blood vessels feeding it, would shed more material into the bloodstream and be easier to detect. The research on this is surprisingly inconsistent. Some studies in lung cancer have found that lymphovascular invasion predicts circulating tumor DNA detection, while others have found that vascular invasion is only marginally correlated or not correlated at all.15PubMed Central. Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response The relationship between a tumor’s blood vessel access and how much DNA it actually releases into circulation is not as straightforward as it seems, and likely depends on tumor type, stage, and other microenvironmental factors.
False Signals From Non-Cancer Sources
As liquid biopsy technology has advanced, a new source of confusion has emerged. Some of the DNA mutations picked up by these sensitive blood tests do not come from cancer at all. They come from a phenomenon called clonal hematopoiesis, where blood-forming stem cells in the bone marrow acquire mutations as a person ages. These mutations can mimic cancer-associated genetic changes in a blood test, leading to false-positive results.
Case reports have documented patients whose liquid biopsy results repeatedly flagged concerning mutations, only for further investigation to reveal that the mutations originated in blood cells, not from any tumor.16PubMed Central. Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis While bioinformatics filtering is getting better at distinguishing these signals from real cancer DNA, the problem has not been eliminated.17PubMed Central. False-Positive Liquid Biopsy Assays Secondary to Overlapping Aberrant Methylation from Non-Cancer Disease States For the patient, a false alarm can trigger weeks of anxiety and expensive follow-up procedures. On the other end, a false negative from the same test could provide dangerous reassurance.
The Reassurance Problem
Perhaps the most practical risk of expanding blood-based cancer testing is the psychological effect of a negative result. Research has shown that patients who receive a “clear” result from a cancer investigation can become over-reassured, making them less likely to seek help promptly if new symptoms develop later.18PubMed Central. Over-reassurance and undersupport after a ‘false alarm’: a systematic review of the impact on subsequent cancer symptom attribution and help seeking If someone takes a multi-cancer blood test, gets a negative result, and then dismisses persistent symptoms because “the blood test was fine,” that false confidence could delay a diagnosis. Given how many cancers these tests cannot reliably detect, this is a real and underappreciated concern.
How Blood-Based Screening Compares to Established Methods
New multi-cancer early detection blood tests have generated enormous excitement, but the evidence so far suggests they are complements to existing screening, not replacements. A modeling study comparing blood-based biomarker screening to established methods for colorectal cancer found that the blood test reduced colorectal cancer incidence by about 40% and mortality by about 52% compared to no screening. Those numbers sound impressive until you compare them to colonoscopy, stool DNA tests, and fecal immunochemical testing, all of which achieved incidence reductions in the range of 68-79% and mortality reductions of 73-81%.19PubMed Central. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy
For cancers that already have effective screening programs, blood tests are not yet competitive. Where they may offer genuine value is for cancers that currently have no screening test at all, like pancreatic cancer or ovarian cancer. Even modest detection rates for those cancers could save lives, simply because the alternative is no early detection whatsoever. The challenge is doing that without generating a flood of false positives that lead to unnecessary biopsies and surgeries.
The Cost of Casting a Wider Net
Scaling blood-based cancer screening to a general population raises economic questions that go beyond the price of the test itself. One analysis estimated that adding multiple single-cancer blood tests to standard guideline-based screening for 100,000 adults would cost roughly $329 million per year, compared to about $98 million for a single multi-cancer test added to the same standard screening. Standard screening alone was estimated at about $48 million for that same population.20PubMed Central. Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi‐Cancer Test to Standard‐Of‐Care Screening Much of that cost comes not from the blood draw but from the downstream diagnostic work-ups triggered by positive and false-positive results. Every abnormal result needs imaging, specialist referral, and sometimes biopsy to determine whether cancer is actually present.
For health systems weighing whether to adopt these tests at scale, the math has to account for both the cancers caught and the false alarms generated. A test that finds one additional cancer for every thousand people screened but sends fifty others through unnecessary CT scans and biopsies has real costs, both financial and human.
Blood Cancers Are the Exception, Not the Rule
The reason leukemia and other blood cancers are detectable on routine blood work is straightforward: the malignant cells are in the blood. A CBC can reveal abnormal white cell counts, unusual cell types, or low red cells and platelets that point directly toward a blood malignancy. A peripheral blood smear, where a technician examines blood cells under a microscope, can reveal the characteristic abnormal cells of lymphomas and leukemias in ways that are impossible for solid tumors.21PubMed Central. Peripheral blood manifestations of lymphoma and solid tumors For solid cancers, the same smear is mainly useful for evaluating the side effects of cancer or its treatment, like anemia or low platelet counts, not for detecting the cancer itself.
This distinction is the most important thing to understand about cancer and blood work. The question is not really whether your blood tests are sensitive enough. For most solid tumors, the cancer is simply not playing on the field that routine blood work monitors. It is growing in tissue, separated from the blood by layers of cells, barriers, and biological noise, and nothing about a standard lab panel is designed to peer through those layers.